Breaking News

Aji Bio-Pharma, CytoDyn Enter COVID-19 Mfg. Pact

Aji Bio-Pharma provides drug product aseptic fill finish services for CytoDyn's Leronlimab, currently being used in clinical trials for COVID-19 patients

By: Contract Pharma

Contract Pharma Staff

Ajinomoto Bio-Pharma Services (Aji Bio-Pharma) has entered a manufacturing services agreement with CytoDyn Inc., a late stage biotechnology company, for the supply of the investigational new drug, leronlimab (PRO 140), which is currently being used in clinical trial protocols for Mild-to-Moderately Ill and Severely Ill COVID-19 patients. Aji Bio-Pharma provides drug product aseptic fill finish services for CytoDyn. Leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters